Company: AGIO
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001439222-25-000116
Chunk: 175

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 8
Chunk 175
---
 observable, directly or indirectly, for substantially the full term of the asset or liability.Level 3 – Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.

9

The following table summarizes our cash equivalents and marketable securities measured at fair value and by level on a recurring basis as of September 30, 2025:(In thousands)Level 1Level 2Level 3TotalCash equivalents$52,129 $1,309 $— $53,438 Total cash equivalents52,129 1,309 — 53,438 Marketable securities:Certificates of deposit— 2,674 — 2,674 U.S. Treasuries— 289,187 — 289,187 Government securities— 176,455 — 176,455 Corporate debt securities— 696,175 — 696,175 Total marketable securities— 1,164,491 — 1,164,491 Total cash equivalents and marketable securities$52,129 $1,165,800 $— $1,217,929 Cash equivalents and marketable securities have been initially valued at the transaction price and are subsequently valued, at the end of each reporting period, utilizing third-party pricing services or other observable market data. The pricing services utilize industry standard valuation models, including both income and market-based approaches, and observable market inputs to determine value. After completing our validation procedures, we did not adjust or override any fair value measurements provided by the pricing services as of September 30, 2025.There have been no changes to the valuation methods during the nine months ended September 30, 2025, and we had no financial assets or liabilities that were classified as Level 3 at any point during the nine months ended September 30, 2025.

4. Marketable Securities

Our marketable securities are classified as available-for-sale pursuant to ASC 320, Investments – Debt and Equity Securities, and are recorded at fair value. Unrealized gains and losses are included as a component of accumulated other comprehensive income (loss) in the condensed consolidated balance sheets and statements of stockholders’ equity, and a component of total comprehensive income (loss) in the condensed consolidated statements of comprehensive (loss) income, until realized. Unrealized losses are evaluated for impairment under ASC 326, Financial